Ascension Health will form a joint venture with a division of Envision Healthcare to provide an array of post-acute services, including home care, hospice care, and infusion therapy.
Ascension Health will form a joint venture with a division of Envision Healthcare to provide an array of post-acute services. The arrangement will include home care, hospice care, and infusion therapy, and under the agreement Envision’s subsidiary, Evolution Health, will be an exclusive partner to provide these services.
The new joint venture will include 5 of Ascension Health’s 23 communities and will begin at the end of this year. According to estimates, revenues should be $75-$100 million, and Ascension expects to expand into additional communities over the next 3 years.
“This agreement furthers Ascension’s focus on delivering person-centered care to individuals in a variety of settings, which is key to our efforts to manage the health of patient populations,” Anthony R. Tersigni, EdD, FACHE, president and chief executive officer (CEO) of Ascension, said in a statement. “Providing service in the home and through alternative facilities to people in need of care, including those who are poor and vulnerable, is one way we extend our ministry beyond hospital walls and reach individuals and families where and when they need us.”
The partnership will expand the footprint of Evolution Health by providing services in new markets. President and CEO William A. Sanger expects that working together with Ascension to deliver post-acute and home care services will improve both patient outcomes and satisfaction.
The Ascension Health Senior Care unit was only formed on July 30 and ranks as the second-largest not-for-profit long-term care provider in the United States. The organization oversees 5,568 senior care/senior living beds and 3 Program of All-inclusive Care for the Elderly.
“We believe there is much to be learned by working with Evolution Health in a way that ensures the most effective and efficient care across our national health ministry in support of our Mission of serving all persons,” added Robert J. Henkel, FACHE, president and CEO of Ascension Health, a direct subsidiary of Ascension.
Health Equity & Access Weekly Roundup: November 23, 2024
November 23rd 2024Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Read More
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More